Search Results 1761-1770 of 18765 for Relapse
The secondary objectives include; evaluation of morphologic relapse free survival (RFS), evaluation of overall survival (OS), assessment of the the survival ...
Also, to improve disease control by decreasing the number of spinal relapses for patients who achieve a complete response (CR) or partial response (PR) and ...
"Currently there are six different CAR-T cell therapies approved for treatment of relapsed blood cancers. While the results are impressive, not everyone ...
... Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL). Rochester ... Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). A Blood ...
The purpose of this study is to assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid ...
Patients at high risk of relapse are eligible for InPACT-pelvis, where they are randomised to either: P. prophylactic PLND Q. no prophylactic PLND. Rare ...
Patients at high risk of relapse are eligible for InPACT-pelvis, where they ... A Study to Evaluate VSV-hIFNbeta-NIS to Treat Patients with Relapsed/Refractory ...
... relapsed after or is refractory to prior therapies, including proteasome inhibitors (PIs), immunomodulators (IMiDs) and anti-CD38 targeted therapies ...
To prevent relapses, Mayo Clinic uses steroid-sparing immunosuppressants. "We find that patients often can be weaned off immunotherapy after 2 to 5 years ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.